How to Buy Spero Therapeutics Stock
Spero Therapeutics Inc
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States.
Spero Therapeutics stock last closed at $2.77, down 4.81% from the previous day, and has decreased 2.81% in one year. It has overperformed other stocks in the Biotechnology industry by 0.69 percentage points. Spero Therapeutics stock is currently +53.89% from its 52-week low of $1.80, and -13.98% from its 52-week high of $3.22.
As of Jun 16, 2026, there are 57.9M SPRO shares outstanding. The market value of SPRO is $160.39M. In the past 24 hours, 1.42M SPRO shares were traded.
How to Buy Spero Therapeutics Stock
Wondering how to invest in Spero Therapeutics stock? Here's how.
- Decide where to buy Spero Therapeutics stock: You need to decide on an online brokerage, but don't worry - we've tried dozens of stock brokerages and apps to help you decide where to buy Spero Therapeutics stock.
- Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Deposit funds into your brokerage account: Choose your payment method and add your info.
- Research Spero Therapeutics stock: The Spero Therapeutics ticker symbol is SPRO. Is Spero Therapeutics stock a good investment? Should you buy shares of SPRO? How do SPRO's underlying business fundamentals look? Do top analysts think Spero Therapeutics is a good buy? Why has SPRO's stock price moved recently? (Hint: Our stock research tools can help you figure out if SPRO is a good stock to buy).
- Execute your SPRO trade: Decide if you will purchase SPRO shares at the current market price or use a limit order to buy SPRO stock at a specific price.
- Get the latest scoop on your investment in SPRO: Create a watchlist to key updates about your new investment in Spero Therapeutics stock.
Step 1: Decide where to buy Spero Therapeutics stock
You will need a brokerage account in order to access the NASDAQ market and buy SPRO shares.
Our favorite brokerage: eToro
We believe that eToro is the best online stock brokerage. eToro gives you:
- You can invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to world markets: From Technology to Healthcare, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top stock exchanges.
- Social investing: eToro offers a community of more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've selected your brokerage, it's time to fill out some personal details so you are able to buy SPRO stock today.
How to Start a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal details to create a new trading account.
- Send your data by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you've created your account on the best stock trading app for beginners, you can securely and quickly fund your account:
Check out the walkthrough below to see the process of depositing money into your brokerage account.
Step 4: Research Spero Therapeutics stock
After you have decided on the best place to buy Spero Therapeutics stock, it's crucial to evaluate their stock before you invest, so you actually understand the risk as well as the upside.
Spero Therapeutics shares at a glance
SPRO Due Diligence Checks
WallStreetZen was built to help everyday investors perform more accurate fundamental analysis quickly.
You can view all of the due diligence checks on SPRO's stock page.
Is SPRO stock properly valued?
Analysts use many financial metrics, analyses, models, and charts to gauge SPRO's fair value.
Using relative valuations methods:
- SPRO could be undervalued based on its P/E ratio of 10.26x, relative to Biotechnology industry P/E ratio of 16.03x
- SPRO may be undervalued based on its P/B ratio of 3.03x, relative to Biotechnology industry P/B ratio of 4.86x
- SPRO could be undervalued based on its PEG ratio of 0.22x
You can access additional valuation analysis on SPRO's stock here.
SPRO Financial Summary
Positive Financial Indicators:
- SPRO earnings of $15.50M is not enough to cover its interest payments.
- Total SPRO debt is lower than 5 years ago, relative to shareholder equity.
- SPRO has a low debt to equity ratio of 0.12.
- SPRO's operating cash flow of $7.24M allows it to safely service it's debt of $2.47M.
- There are more short-term assets than long-term liabilities on the SPRO balance sheet.
- There are more short-term assets than short-term liabilities on the SPRO balance sheet.
- SPRO profit margin has gone up from -156.5% to 24.9% in the past year.
You can dive deeper into what analysts are saying on the Spero Therapeutics stock forecast page.
SPRO Trading Indicators
Is SPRO Making Money?
Last year, SPRO earnings were $15.24M. During the last 2 year, SPRO's earnings have grown by -21.67% per year. This was slower than the Biotechnology industry average of 12.67%.
Last year, SPRO revenue was $61.19M. In the past five year, SPRO's revenue has gone up by 32.59% per year. This was faster than the Biotechnology industry average of 32.16%.
Learn more about SPRO's earnings and revenue performance here.
What are SPRO insiders up to?
In the past year, insiders at SPRO have sold more shares than they have bought.
Esther Rajavelu, Chief Executive Officer Chief Financial Officer and Chief Business Officer of SPRO, was the latest SPRO insider to sell. They sold $63,352.40 worth of SPRO shares on May 4, 2026.
Get more info about who owns SPRO shares here.
Does SPRO provide a stable income stream?
No, Spero Therapeutics doesn't provide an income stream by paying out dividends.
Get opinions from other traders
One of the biggest reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other community members have to say.
Step 5: Execute your SPRO trade
You have two primary types of orders:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are usually sufficient. - Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
If you want to be certain you're buying or selling at a specific price limit, use a limit order.
Hit the Open Trade button and eToro will execute the order.
If you want additional assistance investing in stocks on eToro, watch the helpful video below:
Step 6: Get the latest scoop on your investment in SPRO
Now that you own some SPRO shares, you'll want to keep up with your new stock purchase.
Create a watchlist to get the latest updates about your SPRO stock.
SPRO Feed
How to Buy Stock in Spero Therapeutics
To summarize, here are the 6 steps for buying Spero Therapeutics stock:
- Decide where to buy Spero Therapeutics stock
- Create your brokerage account
- Deposit funds into your brokerage account
- Research Spero Therapeutics stock
- Execute your SPRO trade
- Get the latest scoop on your investment in SPRO
If you require a online brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to get the latest scoop on your investment in Spero Therapeutics, create a watchlist on WallStreetZen today.
Related "How To" Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.